| 3.71 -0.36 (-8.85%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.59 | 1-year : | 6.76 |
| Resists | First : | 4.78 | Second : | 5.78 |
| Pivot price | 3.82 |
|||
| Supports | First : | 3.17 | Second : | 2.63 |
| MAs | MA(5) : | 4.07 |
MA(20) : | 3.9 |
| MA(100) : | 4.99 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.4  |
| %K %D | K(14,3) : | 54.7 |
D(3) : | 65.3 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 25 | Low : | 3.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACXP ] has closed above bottom band by 42.6%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.04 - 4.08 | 4.08 - 4.1 |
| Low: | 3.61 - 3.64 | 3.64 - 3.66 |
| Close: | 3.67 - 3.72 | 3.72 - 3.75 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Thu, 13 Nov 2025
Acurx Pharmaceuticals Eyes Turnaround After Reverse Stock Split - Finimize
Wed, 12 Nov 2025
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update - Yahoo Finance
Mon, 27 Oct 2025
Acurx Pharmaceuticals (NASDAQ: ACXP) sets Nov 12 call on Q3 2025 results, business update - Stock Titan
Thu, 09 Oct 2025
Acurx Pharmaceuticals granted Australian patent for antibiotics - Investing.com
Wed, 08 Oct 2025
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions - ts2.tech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 35 (K) |
| EPS | -8.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.7 % |
| Return on Equity (ttm) | -291.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.46 |
| PEG Ratio | 0 |
| Price to Book value | 1.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|